-
Characteristics of Patients Initiating Glucagon-like Peptide-1 (GLP-1) Receptor Agonists (RAs) for Cardiometabolic Risk Reduction in a Medicare Population
Mar 10, 2025, 14:00 PM -
Market Access as Defined by Professionals with Market Access Backgrounds - Scoping Review
Mar 10, 2025, 14:00 PM -
The Changing Impact of the Inflation Reduction Act on Payer Utilization Management- Insights from an Ongoing Quantitative Survey
Mar 10, 2025, 14:00 PM -
Canada’s Evolving Market for Biosimilars and What It Means for Payers
Mar 10, 2025, 14:00 PM -
Modeling the Potential Public Health Impact and Cost-Effectiveness of BNT162b2 COVID-19 Adapted Booster Vaccination in Dominican Republic
Mar 10, 2025, 14:00 PM -
Healthcare Utilization and Costs in New Users of Once-Weekly GLP-1 Receptor Agonists vs Other Glucose-Lowering Therapies Among Medicare Beneficiaries With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease
Mar 10, 2025, 14:00 PM -
A Targeted Literature Review of Patient Perspectives of Placebo Use in Clinical Trials: How Can the Patient Voice Help Drug Developers in Trial Design, Recruitment, and Retention?
Mar 10, 2025, 14:00 PM -
Mapping Health-Related Quality of Life (HRQoL) Measures to Preference Based Measures in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): A systematic literature review
Mar 10, 2025, 14:00 PM -
An Overview of the Patient Journey and Treatment Utilization in Patients With Prurigo Nodularis
Mar 10, 2025, 14:00 PM -
Efficiency Benefits and Practice Value of Alcon's Digital Cataract Surgery Planning System
Mar 10, 2025, 14:00 PM -
Challenges for PAIC in Rare Diseases: Results of a Systematic Literature Review
Mar 10, 2025, 14:00 PM -
Nirsevimab for RSV Prevention in Hong Kong Infants: A Cost-Effectiveness Analysis
Mar 10, 2025, 14:00 PM -
The Impact of Meeting Orphan Criteria on Reimbursement Decisions and ICERs in Scotland
Mar 10, 2025, 14:00 PM -
Characterizing Improvements in Physical Functioning with PROMIS-PF and In-Trial Exit Interviews: A Mixed-Methods Analysis to Understand the Meaningful Changes Experienced by TGCT Patients on Vimseltinib in the MOTION Trial
Mar 10, 2025, 14:00 PM -
What Drug Characteristics Explain the Wide range of Manufacturer Rebates?
Mar 10, 2025, 14:00 PM -
An Economic Model Exploring the Impact of Formulary Restrictions on the Incidence and Cost of Clinical Events in Patients with Non-Valvular Atrial Fibrillation Receiving Direct Oral Anticoagulants in the United States
Mar 10, 2025, 14:00 PM -
Modeling Challenges and Critiques in Economic Evaluations of Medical Devices: A Review of NICE Medical Technologies Guidance
Mar 10, 2025, 14:00 PM -
Measuring Patient- and Carer-Reported Outcomes Following Genome Sequencing for Rare Disease Diagnosis: A Psychometric Assessment of Outcome Measurement Instruments
Mar 10, 2025, 14:00 PM -
Breaking Linguistic Barriers: Cross-Language HEOR & Evidence Integration Through GenAI
Mar 10, 2025, 14:00 PM -
One Size Doesn’t Fit All: Learnings from a Pilot Survey Assessing Preferences for Improvement vs Worsening of Healthcare Professionals
Mar 10, 2025, 14:00 PM
